Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018563 · ClinicalTrials.gov registry record · Phase 2
An Open Label Extension Study of the Efficacy of MORAb-003
A Phase 2 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01018563: Clinical Trial Phase 2 study, sponsored by Morphotek.
NCT01018563 is a Phase 2 study that was terminated before completion, run by Morphotek. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018563, a Phase 2 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.
Primary Outcome
The duration of CA125 response, was defined the time from the date of the initial CA125 response (i.e., prior to enrollment in the parent study, was the starting point for assessment) to the first documentation of progressive disease (PD) by either Gynecologic Cancer Inter Group (GCIG) criteria for CA125 level or by the date of death due to any cause, whichever occurred first. Disease progression per CA125 was defined as the first of 2 consecutive CA125 values greater than (\>) twice the upper l
Interventions
- DRUG MORAb-003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-01-13 |
| Est. Completion | 2013-03-05 |
| Phase | Phase 2 |
Why NCT01018563 stopped before completion
NCT01018563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which MORAb-003 is the first listed.
NCT01018563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018563 about?
NCT01018563 is a clinical study titled "An Open Label Extension Study of the Efficacy of MORAb-003". An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.
What is the current status of trial NCT01018563?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2010-01-13. Estimated completion is 2013-03-05.
What interventions are being tested in trial NCT01018563?
The interventions under investigation include: MORAb-003 (DRUG).
Who is sponsoring clinical trial NCT01018563?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018563's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI